Accéder au contenu
Merck
  • Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.

Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.

Bioorganic & medicinal chemistry (2008-05-10)
Cécile Gasse, Dominique Douguet, Valérie Huteau, Gilles Marchal, Hélène Munier-Lehmann, Sylvie Pochet
RÉSUMÉ

A series of N(1)-(4-substituted-benzyl)-pyrimidines were synthesized as potential inhibitors of thymidine monophosphate kinase of Mycobacterium tuberculosis (TMPKmt). Key SAR parameters included the chain length substitution in para position of the benzyl ring, the functional group terminating the alkyl chain, and the substituent on the C-5 pyrimidine ring. Synthesized molecules were assayed against both recombinant enzyme and mycobacteria cultures. The most potent compounds have K(i) values in the micromolar range and an MIC(50) of 50microg/mL against Mycobacterium bovis. These results will guide the design of a new generation of lead compounds.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
5-bromo-2′-désoxyuridine, ≥99% (HPLC)
Sigma-Aldrich
Thymidine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Thymidine, ≥99%
Sigma-Aldrich
5-bromo-2′-désoxyuridine, BioUltra, ≥99%